On April 19, MGI, a world-leading life science company, announced partnership with Nalagenetics (NALA). The aim of the partnership is to co-develop low coverage whole genome sequencing for risk prediction and pharmacogenomics through optimizing Next Generation Sequencing (NGS) workflow based on MGI’s sequencing devices and products.
The collaboration plans to use NALA’ Clinical Decision Support, a software medical device, to analyze whole genome sequencing data sets generated by MGI’s DNBSEQTM sequencing platform*, and generate clinical-grade reports for pharmacogenomics and polygenic risk scores. Although NGS is an effective way to capture a large amount of genomic information to guide and tailor clinical management and treatment,1 NGS workflows are complicated to adopt in clinical settings. NALA is dedicated to help implement clinical genetic testing in Southeast Asia with strong expertise in pharmacogenetics, assay development, and AI-linked genetics analysis for pharmacological phenotypes and risk prediction.
More and more hospitals today are adopting sequencing for personalization of medicine in oncology, cardiovascular conditions, and others. According to Levana Sani, CEO of Nalagenetics, “One of the biggest challenges is recommending follow up action that makes sense for the local market, for example list of alternative therapies and screening procedures that lead to cost-effectiveness. We are glad to work with MGI to co-develop products and offer services to answer local needs”.